Q2 2025 EPS Estimates for Exelixis, Inc. (NASDAQ:EXEL) Lowered by Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Zacks Research reduced their Q2 2025 earnings estimates for shares of Exelixis in a note issued to investors on Monday, September 16th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will earn $0.34 per share for the quarter, down from their prior forecast of $0.37. The consensus estimate for Exelixis’ current full-year earnings is $1.54 per share. Zacks Research also issued estimates for Exelixis’ Q3 2025 earnings at $0.34 EPS and Q1 2026 earnings at $0.39 EPS.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million.

A number of other brokerages also recently weighed in on EXEL. JMP Securities reissued a “market outperform” rating and issued a $29.00 price target on shares of Exelixis in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday. Truist Financial reaffirmed a “buy” rating and set a $33.00 price objective (up previously from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. Oppenheimer reiterated an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Finally, StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Exelixis Stock Performance

NASDAQ:EXEL opened at $26.42 on Thursday. Exelixis has a 52 week low of $18.64 and a 52 week high of $27.83. The firm has a 50-day moving average price of $25.12 and a two-hundred day moving average price of $23.31. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of 41.28, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54.

Insider Activity at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the sale, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of Exelixis stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now directly owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Dana Aftab sold 20,883 shares of Exelixis stock in a transaction on Monday, August 12th. The stock was sold at an average price of $27.06, for a total transaction of $565,093.98. Following the completion of the transaction, the executive vice president now owns 500,107 shares in the company, valued at approximately $13,532,895.42. The disclosure for this sale can be found here. Insiders have sold a total of 302,858 shares of company stock valued at $7,980,629 over the last 90 days. 2.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Exelixis

A number of hedge funds have recently modified their holdings of the company. Fisher Asset Management LLC boosted its holdings in shares of Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the period. Rise Advisors LLC bought a new stake in shares of Exelixis during the 1st quarter valued at about $28,000. Park Place Capital Corp bought a new position in Exelixis in the second quarter worth about $45,000. GAMMA Investing LLC lifted its holdings in Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,041 shares during the period. Finally, EntryPoint Capital LLC raised its position in shares of Exelixis by 537.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.